Imatinib

Synonym(s): Glivec  |  STI571

Class: Small molecule antibacterial agent

Details of activity:	Active against Mycobacterium tuberculosis and Mycobacterium marinum
Description:	Synthetic compound; repurposed FDA-approved anticancer drug (tyrosine kinase inhibitor); shows synergistic effect with antituberculosis drugs
Year first mentioned:	2012
Development status:	Experimental

Chemical structure(s):
Canonical SMILES:	CC1=CC=C(C=C1NC2=NC(=CC=N2)C3=CN=CC=C3)NC(=O)C4=CC=C(C=C4)CN5CCN(C)CC5
Isomeric SMILES:	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI:	InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
InChI Key:	KTUFNOKKBVMGRW-UHFFFAOYSA-N

External links:
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/5291
Main Source:	https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003946
Citations:	https://www.sciencedirect.com/science/article/pii/S1931312811003295?via%3Dihub https://www.nature.com/articles/s41598-021-01526-6 https://pmc.ncbi.nlm.nih.gov/articles/PMC3684563/